Glooko Targets the Trillion-Dollar Diabetes Market with Platform Covering 10,000+ Clinics and Millions of Users

Diabetes, a chronic disease afflicting hundreds of millions of people worldwide. According to data released by the International Diabetes Federation (IDF), global healthcare expenditures for adult diabetes patients reached $966 billion in 2021 and are projected to exceed $1 trillion by 2030. Meanwhile, disease management remains cumbersome and complex. Traditional blood glucose monitoring methods are not only inefficient but also create significant barriers to communication between patients and physicians. In the field of diabetes management, the application of digital health technologies has become a key breakthrough for future industry competition.

Founded in 2010, Glooko leverages mobile devices and cloud computing technology to connect patients, physicians, and medical devices, enabling seamless collection, analysis, and sharing of diabetes data. To date, Glooko’s diabetes management platform has been used by more than 4.4 million people with diabetes worldwide and deployed in over 10,000 clinics globally. The platform has also been utilized in more than 20 clinical trials to facilitate patient recruitment and data collection.

Digital Technologies Reshape the Chronic Disease Management Ecosystem. As diabetes is one of the primary conditions in chronic disease management, a digital ecosystem for diabetes care has also been established. Building on this foundation, Glooko leverages its MeterSync™ technology to enable patients with diabetes to seamlessly synchronize blood glucose data across devices.

Specifically, patients can easily transmit data from over 25 different brands of blood glucose meters directly to more than 30 models of Apple or Android smartphones. This functionality is made possible by Glooko’s acquisition of data specifications and standard licenses from major blood glucose meter manufacturers, enabling its product to be compatible with approximately 80% of the blood glucose meters on the market.

Subsequently, through the Glooko™ app, patients with diabetes can enjoy more convenient and comprehensive health management services. They can not only record key information such as carbohydrate intake, insulin usage, and medication adherence on the app, but also view charts and statistical data generated from historical records in real time. In addition, patients can share their health reports with their primary care physicians via email, print, or fax, facilitating timely information sharing.

Furthermore, Glooko’s mobile and cloud-based solutions provide support to healthcare institutions. Among these, the Glooko Population Tracker™—a patient population tracking and management system—enables institutions to collect and analyze big data, thereby facilitating decision-making. Through this system, institutions can more precisely implement stratified risk management for diabetic populations, enhancing the overall standard of care.

In terms of information security, Glooko consistently regards the protection of patient data as the cornerstone of its business. To this end, Glooko has achieved HIPAA compliance, ensuring full adherence to U.S. government regulations and standards concerning medical privacy and security, thereby safeguarding the integrity and confidentiality of patient data.

Currently, Glooko is advancing to the next stage of health data tracking technology—predictive care. By fully leveraging patient data and providing healthcare institutions with patient insights and decision-support algorithms, Glooko enables more precise diabetes care. Meanwhile, Glooko offers health systems and disease management organizations a more efficient tool for population management and analytics, helping them focus greater attention on high-risk patients and improve long-term adherence to treatment plans.

In 2018, Glooko’s innovative mobile insulin dosing system received FDA approval. Designed for patients with type 2 diabetes to titrate long-acting insulin, the system automatically retrieves blood glucose data from users’ glucometers, insulin pumps, insulin pens, or continuous glucose monitoring (CGM) systems, thereby eliminating the cumbersome step of manually entering fasting blood glucose values. By intelligently analyzing blood glucose levels in accordance with healthcare institutions’ treatment plans and clinical guidelines, the system also recommends corresponding insulin dose adjustments.

Notably, Glooko employs a distinctive business model. Rather than selling its products directly to patients, it markets to healthcare system stakeholders, such as physicians and clinics, who then provide the solution to their patients. In terms of pricing, Glooko charges healthcare systems a monthly subscription fee based on the number of patients.

The primary reason is that Glooko’s solution is built upon its core resources and key partners. Core resources—including database management, hospital relationships, analytics development, and clinic physicians—deliver convenient data management and analytics services to patients with diabetes through various channels, such as mobile apps, enterprise-grade meter reading systems, and blood glucose meters. In terms of key activities, Glooko focuses on upload rate prediction, data analytics, and data sharing, while collaborating closely with professionals such as hospital administrators and insurance companies.

Glooko has been actively expanding its footprint through strategic acquisitions. In January 2022, it announced the acquisition of xbird, a German artificial intelligence-based diabetes management company. xbird monitors patient activity using sensors and wearable devices, leverages artificial intelligence and machine learning technologies to identify potential issues, and alerts users to take action. Glooko plans to integrate xbird’s software into its platform to further enhance its analytical capabilities. In March of the same year, Glooko announced the acquisition of DIABNEXT, a French company that helps patients manage diabetes through a digital health platform. DIABNEXT’s mobile application will complement Glooko’s product portfolio by monitoring patient data and providing remote care services.

Furthermore, Glooko has spared no effort in pursuing mergers and partnerships. In September 2016, it merged with Diasend to form a single company operating under the Glooko name. The combined platform enables data downloads from more than 160 different devices, covering over 95% of diabetes devices worldwide. In May 2021, Glooko announced a collaboration with Eli Lilly and Company to provide services for patients with diabetes using Lilly’s connected insulin pens.

Globally, the diabetes management market is undoubtedly a vast blue ocean. It is projected that by 2025, the number of diabetes patients in China will surge to 320 million. In particular, following the intense competition among numerous diabetes management platforms, the market trend is gradually shifting from simple doctor-patient connectivity services to a full-lifecycle service model. In this process, digital technologies are serving as a breakthrough point to reshape diabetes management workflows and create an entirely new service model for diabetes care.

Companies such as Zhiyun Health, Ruikongtang, and Tanghushi are accelerating their strategic deployments, driving the rapid development of the diabetes management industry. Zhiyun Health’s hospital-based solution, primarily centered on SaaS services—Zhiyun Yihui—has achieved digitalization and standardization of chronic disease management processes within hospitals. In a healthcare system dominated by public hospitals, Zhiyun Health has rapidly entered the market and gained user recognition through its unique AIM model. The company has also demonstrated strong performance in the out-of-hospital market. Its pharmacy SaaS system, Zhiyun Wenzhen, empowers pharmacies with digital technologies, enhancing operational efficiency and prescription rationality, while providing chronic disease patients with more convenient and compliant pharmaceutical services. As of June 30, 2023, over 200,000 pharmacies had installed Zhiyun Wenzhen, covering 32% of pharmacies across China, with online service encounters exceeding 80 million, making it the largest online medical service provider in the country.

Meanwhile, Ruikongtang leverages a multi-dimensional, standardized blood glucose assessment system based on big data. Through data analytics models, it provides medical teams with precise insights into blood glucose fluctuation patterns and transmits data in real time to both hospital intranets and the cloud, enabling more timely and personalized intervention plans for patients. Furthermore, Ruikongtang is compatible with dozens of glucometer models, covering 90% of mainstream brands, thereby establishing itself as a leading technology platform in the industry for compatibility and adaptability.

Looking ahead, with continuous technological advancements and an increasingly mature market, the diabetes management industry is poised for broader growth prospects. Leading enterprises such as Zhiyun Health and Ruikongtang, along with emerging innovators, will leverage digital innovation to drive transformation and development in the sector, delivering higher-quality, more convenient health management services to patients with diabetes.